Baidu
map

NEJM:手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率

2022-02-12 Nebula MedSci原创

手术前后新辅助/辅助治疗时加用派姆单抗可显著提高早期三阴性乳腺癌患者的无事件生存率

KEYNOTE-522是一项3期临床试验,旨在评估免疫检查点抑制剂派姆单抗加入新辅助化疗与单用新辅助化疗相比对早期三阴性乳腺癌患者预后的影响。初步分析显示,新辅助化疗方案加用派姆单抗可显著提高早期三阴性乳腺癌患者在进行根治性手术时的病理完全缓解率(定义:乳腺和淋巴结中均没有浸润性癌)

本文汇报了该试验的另一项主要终点,即无事件生存率。

该试验将既往未治疗过的II或III期三阴性乳腺癌患者以2:1的比例随机分成两组,接受新辅助化疗+4个疗程的派姆单抗(200 mg)或安慰剂+紫杉醇和卡铂,继以4个疗程的派姆单抗或安慰剂+阿霉素-环磷酰胺或表阿霉素-环磷酰胺。根治性手术后,患者继续接受辅助化疗+派姆单抗或安慰剂治疗9个疗程(1疗程/3周)。主要终点是病理完全缓解率和无事件生存率。

两组患者的无事件生存率

共招募了1174位患者,其中784位被分至派姆单抗-化疗组,390位被分至安慰剂-化疗组。截止2021年3月23日(第4次预定的中期分析时),中位随访了39.1个月。第36个月时,派姆单抗-化疗组和安慰剂-化疗组估计的无事件生存率分别是84.5和76.8%(风险比 0.63,p<0.001)。不良事件主要发生在新辅助治疗期,这与已明确的派姆单抗及化疗的安全性问题一致。

两组患者的总生存期

综上,对于早期三阴性乳腺癌患者,新辅助派姆单抗联合化疗,再加上术后派姆单抗辅助治疗可相比单用新辅助化疗显著提高无事件生产率。

原始出处:

Peter Schmid, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386:556-567

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048105, encodeId=44ae2048105a6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Feb 15 04:09:43 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253491, encodeId=26921253491b2, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256878, encodeId=39fe12568e8c9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458822, encodeId=7676145882247, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048105, encodeId=44ae2048105a6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Feb 15 04:09:43 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253491, encodeId=26921253491b2, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256878, encodeId=39fe12568e8c9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458822, encodeId=7676145882247, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048105, encodeId=44ae2048105a6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Feb 15 04:09:43 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253491, encodeId=26921253491b2, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256878, encodeId=39fe12568e8c9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458822, encodeId=7676145882247, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048105, encodeId=44ae2048105a6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Feb 15 04:09:43 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253491, encodeId=26921253491b2, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256878, encodeId=39fe12568e8c9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458822, encodeId=7676145882247, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Mon Feb 14 12:09:43 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
    2022-02-14 xlysu

相关资讯

JAMA Oncol:九个乳腺癌风险基因变异与不同亚型乳腺癌风险的相关性

在不超过40岁的年轻女性中,这9个基因与27.3%的三阴性乳腺癌相关

Clin Cancer Res:Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌

Lacnotuzumab+吉西他滨+卡铂治疗晚期三阴性乳腺癌的效果与单用吉西他滨+卡铂的相当。

Cell Metab:“饿死”肿瘤的想法真的可实现了?科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸!

FMD对正常、癌症和CSCs有广泛和不同的影响,允许快速识别靶向饥饿逃逸途径,并提供了一种可能适用于许多恶性肿瘤的方法。

Cell Research:“高危”三阴性乳腺癌有望增添代谢治疗靶点,“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱

肿瘤代谢视角下的相关研究成果有效丰富了三阴性乳腺癌研究的内涵,巩固了‘临床问题-科学研究-临床实践’的研究闭环。

欧盟授予 Trodelvy 用于治疗乳腺癌的营销授权

随着欧盟的最新批准,欧洲患有转移性三阴性乳腺癌的患者现在可以接受吉利德科学公司的 Trodlevy 作为治疗的一部分。

J Clin Oncol:三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后(LTOs)

CALGB 40603研究表明,卡铂和贝伐珠单抗的加入尽管获得较高的pCR率,但并不能改善患者的LTOs。获得pCR患者的预后较残留疾病(RD)患者要好。

Baidu
map
Baidu
map
Baidu
map